Cost-effectiveness of self-sampling and enhanced strategies for HPV prevention among men who have sex with men in China: a modeling study.

IF 7 1区 医学 Q1 MEDICINE, GENERAL & INTERNAL
Zhen-Hao Wu, Yu-Jing An, Zhen-Xing Chu, Xin-Ru Li, An-Yang Hou, Yong-Jun Jiang, Qing-Hai Hu
{"title":"Cost-effectiveness of self-sampling and enhanced strategies for HPV prevention among men who have sex with men in China: a modeling study.","authors":"Zhen-Hao Wu, Yu-Jing An, Zhen-Xing Chu, Xin-Ru Li, An-Yang Hou, Yong-Jun Jiang, Qing-Hai Hu","doi":"10.1186/s12916-025-04131-w","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Human papillomavirus (HPV) testing on self-collected samples (self-sampling) can address the challenges with facility-sampling among men who have sex with men (MSM). However, its cost-effectiveness and effective combination with vaccination must be evaluated, particularly in the absence of national HPV vaccination immunization programs among men.</p><p><strong>Methods: </strong>We constructed a decision-analytic Markov model to assess the cost-effectiveness of the status quo, HPV self-sampling at different intervals, vaccination alone, and HPV self-sampling-vaccination combination based on the incremental cost-effectiveness ratio (ICER), from a healthcare system perspective. Univariate and probabilistic sensitivity analyses were conducted to evaluate the robustness of the proposed model.</p><p><strong>Results: </strong>A lifetime cost-effectiveness analysis on a hypothetical cohort comprising 100,000 MSM aged 12 years at baseline projected that combining screening and vaccination generated incremental costs of US$49,638-219,213 million while accruing 189,881-271,564 quality-adjusted life-years (QALYs) compared with the status quo. Incorporating HPV self-sampling significantly improved the cost-effectiveness of traditional interventions. Remarkably, combining annual HPV self-sampling with nine-valent vaccination proved the most cost-effective at a willingness-to-pay (WTP) threshold three times the Chinese per-capita gross domestic product (GDP). This strategy yielded an ICER of $775 per QALY compared to the status quo and was 55.7% possible to be cost-effective with a WTP threshold three times the per-capita GDP, outperforming other strategies.</p><p><strong>Conclusions: </strong>Implementing annual HPV self-sampling along with nine-valent vaccination is projected to be the most cost-effective among MSM in China. Reducing the costs of HPV self-sampling and vaccination is crucial for guaranteeing that future initiatives produce favorable economic outcomes. These findings provide valuable guidance for formulating policies on HPV prevention among MSM in China.</p>","PeriodicalId":9188,"journal":{"name":"BMC Medicine","volume":"23 1","pages":"362"},"PeriodicalIF":7.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12217994/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12916-025-04131-w","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Human papillomavirus (HPV) testing on self-collected samples (self-sampling) can address the challenges with facility-sampling among men who have sex with men (MSM). However, its cost-effectiveness and effective combination with vaccination must be evaluated, particularly in the absence of national HPV vaccination immunization programs among men.

Methods: We constructed a decision-analytic Markov model to assess the cost-effectiveness of the status quo, HPV self-sampling at different intervals, vaccination alone, and HPV self-sampling-vaccination combination based on the incremental cost-effectiveness ratio (ICER), from a healthcare system perspective. Univariate and probabilistic sensitivity analyses were conducted to evaluate the robustness of the proposed model.

Results: A lifetime cost-effectiveness analysis on a hypothetical cohort comprising 100,000 MSM aged 12 years at baseline projected that combining screening and vaccination generated incremental costs of US$49,638-219,213 million while accruing 189,881-271,564 quality-adjusted life-years (QALYs) compared with the status quo. Incorporating HPV self-sampling significantly improved the cost-effectiveness of traditional interventions. Remarkably, combining annual HPV self-sampling with nine-valent vaccination proved the most cost-effective at a willingness-to-pay (WTP) threshold three times the Chinese per-capita gross domestic product (GDP). This strategy yielded an ICER of $775 per QALY compared to the status quo and was 55.7% possible to be cost-effective with a WTP threshold three times the per-capita GDP, outperforming other strategies.

Conclusions: Implementing annual HPV self-sampling along with nine-valent vaccination is projected to be the most cost-effective among MSM in China. Reducing the costs of HPV self-sampling and vaccination is crucial for guaranteeing that future initiatives produce favorable economic outcomes. These findings provide valuable guidance for formulating policies on HPV prevention among MSM in China.

中国男男性行为者自我抽样和强化HPV预防策略的成本效益:一项模型研究。
背景:人类乳头瘤病毒(HPV)检测自采样本(自我抽样)可以解决在男男性行为者(MSM)中进行设施抽样的挑战。然而,必须对其成本效益和与疫苗接种的有效结合进行评估,特别是在缺乏国家男性HPV疫苗免疫规划的情况下。方法:构建决策分析马尔可夫模型,以增量成本-效果比(ICER)为基础,从卫生保健系统的角度,评估现状、HPV不同间隔自采样、单独接种、HPV自采样-疫苗联合接种的成本-效果。进行了单变量和概率敏感性分析,以评估所提出模型的稳健性。结果:对10万名基线年龄为12岁的男男性行为者进行的终身成本效益分析预测,与现状相比,筛查和疫苗接种相结合产生了49,638-219,213万美元的增量成本,同时增加了189,881-271,564质量调整生命年(QALYs)。结合HPV自采样显著提高了传统干预措施的成本效益。值得注意的是,将年度HPV自采样与九价疫苗接种相结合,在支付意愿(WTP)阈值为中国人均国内生产总值(GDP)的三倍时,证明最具成本效益。与现状相比,该策略产生的ICER为每个QALY 775美元,并且在WTP阈值为人均GDP的三倍的情况下,具有55.7%的成本效益可能性,优于其他策略。结论:在中国的男男性行为者中,实施年度HPV自采样和九价疫苗接种预计是最具成本效益的。降低HPV自采样和疫苗接种的成本对于保证未来的举措产生有利的经济结果至关重要。这些发现为中国MSM人群HPV预防政策的制定提供了有价值的指导。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
BMC Medicine
BMC Medicine 医学-医学:内科
CiteScore
13.10
自引率
1.10%
发文量
435
审稿时长
4-8 weeks
期刊介绍: BMC Medicine is an open access, transparent peer-reviewed general medical journal. It is the flagship journal of the BMC series and publishes outstanding and influential research in various areas including clinical practice, translational medicine, medical and health advances, public health, global health, policy, and general topics of interest to the biomedical and sociomedical professional communities. In addition to research articles, the journal also publishes stimulating debates, reviews, unique forum articles, and concise tutorials. All articles published in BMC Medicine are included in various databases such as Biological Abstracts, BIOSIS, CAS, Citebase, Current contents, DOAJ, Embase, MEDLINE, PubMed, Science Citation Index Expanded, OAIster, SCImago, Scopus, SOCOLAR, and Zetoc.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信